A paper from the laboratory of Professor Roland Wolf and Dr Colin Henderson, which is situated in the Jacqui Wood Cancer Centre at Ninewells, has been published in the latest edition of Clinical Cancer Research.
The paper focuses on the development of models in the laboratory which enable detailed prediction of how drugs can be developed and applied in a clinical setting. The aim of these models is to allow a more detailed prediction on drug metabolism and elimination within the body – both of which are key factors in the efficacy of drugs and the side effects they present.
The models have been used to study the metabolism of one particular drug, Osimertinib, which has been developed for use in the treatment of specific types of lung cancer. Previously, the pharmacokinetics of Osimertinib had been poorly predicted, however, these newly-developed models have not only enabled better prediction of the metabolism of Osimertinib, but have also uncovered another pathway of disposition of enzymes in the lung tissue of smokers.
These findings are particularly relevant in the treatment of lung cancer patients as the amount of the drug within the lungs is a key factor of its efficacy. The team behind the research hope these findings will lead to more personalised – and therefore better – treatment for lung cancer patients.
Dr Henderson said, “The aim of our research is to optimise anticancer drug treatments to increasing efficacy and reducing side effects and drug resistance. The current study exemplifies how these model systems can be applied.”